药店提议,在公众咨询之后,自2026年5月1日起,为新西兰的两套CLL组合疗法提供资金。 Pharmac proposes funding two CLL combo therapies in NZ from May 1, 2026, following public consultation.

药学公司拟从2026年5月1日开始为新西兰的慢性淋巴细胞白血病 (CLL) 提供一线治疗的两种联合疗法:venetoclax与ibrutinib和venetoclax与obinutuzumab. Pharmac is proposing to fund two combination therapies—venetoclax with ibrutinib and venetoclax with obinutuzumab—for first-line treatment of chronic lymphocytic leukaemia (CLL) in New Zealand, starting May 1, 2026. 口服治疗旨在延长治疗期,减少化疗的使用,提高生活质量。 The oral treatments aim to extend remission, reduce chemotherapy use, and improve quality of life. 目前私人接受治疗的病人,如果在批准前达到供资标准,可在私人诊所继续接受治疗。 Patients currently receiving treatment privately may continue in private clinics if they met funding criteria before approval. 该提案是在2026年3月4日之前开放的公开协商之后提出的,是扩大癌症护理(包括干细胞移植和更快的治疗机会)的更广泛努力的一部分。 The proposal follows public consultation open until March 4, 2026, and is part of broader efforts to expand cancer care, including stem cell transplants and faster treatment access.